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Using confocal microscopy domination of CD68+/RS1+ cells were
found.
Conclusion: So, low CD68 expression level in ductal gaps tumor
structures is associated with the presence of metastatic regional
lymph nodes.
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Background: To evaluate the expression of markers of sensitiv-
ity to chemotherapy in patients various solid tumors.
Materials and methods: The work includes paraffin blocks
NSCLC patients (n = 486); CRC (n = 262); Breast cancer (n = 55); cer-
vical cancer (n = 19); kidney (n = 35); squamous head and neck
cancer (n = 15); stomach (n = 51); ovarian (n = 25); melanoma
(n = 58); soft tissue sarcomas (n = 52). On our panel discussed
the spectrum of expression of enzymes DPD, TP, TS, ERCC1,
b-tubulin. Measurement of the expression of these genes pro-
duced by polymerase chain reaction in real time according to
the method developed at the Institute of Oncology. NN Petrova.
Results: The combination of markers of sensitivity to fluoropy-
rimidine (low levels of DPD, TS, and low/high TP) was observed in
patients with NSCLC in 30.9%, 41.9% in colorectal cancer, breast
cancer in 31.1%, renal cell carcinona 41.1%, head and neck carci-
noma in 14.3%, of gastric cancer in 42.5% melanoma in 39.5% of
cases. Marker sensitivity to platinum drugs (low ERCC1) occurs
in patients with NSCLC in 68.8%, 57.1% in colorectal cancer, breast
cancer in 55.0%, renal cancer in 70.8% of squamous cell carci-
noma of the head and neck 50, 0% of gastric cancer in 87.9% in
melanoma 63.6% of cases. Marker, is an indirect measure of sen-
sitivity to taxane drugs (low b-tubulin) in patients with NSCLC
diagnosed in 72.7% of cases, in 75% of colorectal cancer, breast
cancer in 66.7%, renal cancer in 92.3% of gastric cancer to
86.6%, melanoma in 73.5%.
Conclusion: The expression of markers in tumor tissue is
heterogeneous. Significant heterogeneity of expression of predic-
tive marker indicates on one hand the futility of the empirical
approach to the choice of therapy, and on the other the need
for their determination in all patients. Information about the
molecular and genetic features of the tumor can afford to
individualize the choice of drug. Objective data about the
informativeness of molecular genetic markers can be obtained
on the basis of randomized clinical trials.
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Background: In previous experiments the self-dependent
antitumor effect of magnetite nanoparticles (NPs) injected in
peritumoral area in form of magnetic fluid (MF) was shown.
Elucidation of the mechanisms of this phenomenon is of theoret-
ical and practical interest. The aim of the study was to investigate
the cellular and ultrastructural changes in the tissue tumors
regressed under the influence of magnetite NPs, as well as the
composition of the cells of the immune system in the peritumoral
area.
Materials and methods: The study was carried on white male
rats, 180–200 g, with transplanted sarcoma 45 (59) or Pliss
lymphosarcoma (50). Special antitumor agents were not used.
Magnetite NPs (10 ± 2 nm) were applied in the form of the
water-based MF. Original MF (20 kA/m) was diluted with saline
in different degree and was injected into peritumoral zone along
the tumor borders at a distance of 1.5 cm twice a week in a vol-
ume of 0.4–0.9 ml (depending on the animal weight) within
3 weeks. Special anti-tumor agents were not used. At the end of
the experiments fragments of the tumor and surrounding tissue
were taken for research. The study of changes in the tumor and
peritumoral area were performed by the methods of cytology, his-
tology, histochemistry, electron microscopy (microscope JEOL
JEM-1011, Japan), flow cytometry, X-ray fluorescence spectroscopy
(spectrometer M4 Tornado Bruker).
Results: At a dilution of the original MF in 30 times the treat-
ment was effective in 75% of animals. Complete and partial (more
than 2-fold) tumor regression was observed in 2/3 cases. In rats
with Pliss lymphosarcoma tumor regression on 70–100% has been
reported in 20–40% cases. The results of microscopic examination
of sarcoma 45 with partial regression showed significant changes
in their immune microenvironment compared with the cases of
progressive tumor growth (p < 0.05–0.01). This was expressed in
the increase in the number of lymphocytes and plasmacytes
(respectively, in 12 and 2.5 fold), and in the appearance of
macrophages and basophils that were missing in tumors with
progressive growth. The results of flow cytometry of tissue from
the tumor as well as from peritumoral zone indicate the predom-
inance of plasmacytes in the case of inhibition of tumor growth
and increasing the proportion of mature T lymphocytes in the
cases of tumor regression (more than 1.5 times, p < 0.05). By
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